A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
Clinical trial NCT01343043 · COMPLETED
Trial details
- NCT number
- NCT01343043
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2012-09-27
- Primary completion
- 2019-06-18
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.